Table 1.
| A Anti-HCV titers in mice immunized with a combination of HCV recombinant proteins in various formulations (n = 5, each group) | ||||
|---|---|---|---|---|
|
| ||||
| Formulations | Anti-HCV titer (geometric mean)a | |||
|
|
||||
| Core | E1E2 | NS3 | NS5b | |
| 40 µg prot no CpG | 3676 | 58813** | 400** | 264** |
| 40 µg prot + 50 µg GpC control | 3676 | 67559** | 16890** | 1838* |
| 40 µg prot + 10 µg CpG | 14703 | 540470 | 77605** | 5572 |
| 40 µg prot + 50 µg CpG | 19401 | 713155 | 2162000 | 6400 |
| 8 µg prot + 10 µg CpG | 5572 | 310419 | 270235** | 1056* |
| 30 µg prot (no E1E2) + 50 µg CpG | 310419* | – | 2853000 | 6400 |
| 10 µg core + 10 µg CpG | 356578** | – | – | – |
| 10 µg E1E2 + 10 µg CpG | – | 540470 | – | – |
| 10 µg NS3 + 10 µg CpG | – | – | 3277000 | – |
| 10 µg NS5b + 10 µg CpG | – | – | – | 6400 |
| B Isotype analysis anti-HCV core, E1/E2, NS3, NS5b antibodies in mice immunized with a combination of HCV recombinant proteins in various formulationsa | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
| |||||||||||||
| Formulations | n | core | E1E2 | NS3 | NS5b | ||||||||
|
|
|
|
|
||||||||||
| IgG1 | IgG2a | IgG2a/IgG1 | IgG1 | IgG2a | IgG2a/IgG1 | IgG1 | IgG2a | IgG2a/IgG1 | IgG1 | IgG2a | IgG2a/IgG1 | ||
| 40 µg prot no CpG | 5 | 91.45 | 23.96 | 0.26* | 5755.02 | 933.62 | 0.16** | 2.98 | 0.30 | 0.10 | 1.76 | 0.56 | 0.32* |
| 40 µg prot + 50 µg GpC control | 5 | 20.45 | 61.79 | 3.02 | 5205.01 | 2400.07 | 0.46** | 61.06 | 38.83 | 0.64 | 9.25 | 3.19 | 0.35 |
| 40 µg prot + 10 µg CpG | 5 | 35.66 | 227.90 | 6.39 | 9948.31 | 28483.17 | 2.86 | 63.25 | 619.15 | 9.79 | 10.29 | 51.85 | 5.04 |
| 40 µg prot + 50 µg CpG | 5 | 34.78 | 759.91 | 21.85 | 10531.34 | 48365.18 | 4.59 | 3820.61 | 18487.89 | 4.84 | 6.94 | 44.55 | 6.42 |
| 8 µg prot + 10 µg CpG | 5 | 5.90 | 253.92 | 43.04 | 6135.46 | 15078.32 | 2.46 | 532.54 | 1967.48 | 3.69 | 1.37 | 2.80 | 2.04 |
| 30 µg prot (no E1E2) + 50 µg CpG | 5 | 3198.93 | 6939.32 | 2.17* | – | – | – | 9580.35 | 40079.00 | 4.18 | 8.34 | 46.50 | 5.58 |
| 10 µg core + 10 µg CpG | 5 | 12746.02 | 2281.84 | 0.18** | – | – | – | – | – | – | – | – | – |
| 10 µg E1E2 + 10 µg CpG | 5 | – | – | – | 18789.08 | 13426.93 | 0.71* | – | – | – | – | – | – |
| 10 µg NS3 + 10 µg CpG | 5 | – | – | – | – | – | – | 22174.25 | 29164.72 | 1.32 | – | – | – |
| 10 µg NS5b + 10 µg CpG | 5 | – | – | – | – | – | – | – | – | – | 66.40 | 14.13 | 0.21 |
a
The anti-HCV titers were compared by using the Mann–Whitney U test.
*
P < 0.05 vs. 40µg prot + 50µg CpG.
**
P < 0.01 vs. 40µg prot + 50µg CpG.
a
The titers of anti-HCV core, E1/E2, NS3 and NS5b IgG1 or IgG2a were determined by endpoint dilution assay and expressed as the geometric means. The IgG2a/IgG1 ratios were provided and compared by using the Mann–Whitney U test.